BPC-157: what the evidence does — and doesn’t — show
One of the most talked-about peptides online has a large animal literature and almost no controlled human data.
What it is
BPC-157 is a 15-residue peptide (GEPPPGKPADDAGLV) derived from a protein found in human gastric juice. “BPC” stands for “body protection compound.”
The animal research
Most of what’s known comes from rodent studies. These report faster healing of tendons, ligaments, muscle and gut tissue, and effects on blood-vessel growth signals. Animal results are a reason to study something in people, not evidence that it works in people.
The human research
A 2025 systematic review of BPC-157 in orthopaedic sports medicine found only one clinical study in people: a retrospective report in which 7 of 12 patients with chronic knee pain said their symptoms improved after injections. There was no control group. The review’s authors concluded that human safety is unknown and urged caution.
Regulatory status
BPC-157 is not an FDA-approved drug. In July 2026 an FDA advisory committee voted 8–6 to recommend allowing compounding pharmacies to use it. That vote is not binding and is not an approval — see our explainer on drug labels. It is also prohibited in sport under anti-doping rules.
Bottom line
Evidence ladder: Animal. Interesting preclinical biology, no controlled human trials, unknown human safety.
Sources
Educational content only — not medical advice. See our Medical disclaimer and Editorial policy.